Buy SGT-151 Online (5f-CUMYL-PeGaCLONE) is a synthetic cannabinoid which has already proved popular with researchers all over Europe and USA.
SGT-151 is a new synthetic cannabinoid chemical that is not controlled in most EU countries for laboratory research. It is also known as CUMYL-PeGaCLONE. Buy top purity SGT-151 and be amongst the first scientists to study this new chemical as part of your laboratory cannabinoid research program.
5F-SGT-151 (5f-CUMYL-PeGaCLONE) is a synthetic cannabinoid which has already proved popular with researchers all over Europe and USA.http://www.kyivpharmaceuticals.com
5F-SGT-151 (5f-CUMYL-PeGaCLONE) is similar in many ways to 5F-ADB, but has a much higher affinity for the CB1 receptor.
Acting upon the Cannabinoid receptors, SGT-151 (AKA Cumyl-Peglacone) has similar effects if not better than any other analogous including STS-135..
SGT-151 is a relatively new cannabimimetic agent, which has already proved popular with researchers all over Europe.
Chem.eu sells SGT-151 via an exclusive agent and in a powder form for the purposes of research alone. As with all our products, it is not suitable for human consumption.
It’s not often a new agent of such good quality is synthesized, so researchers around the world are excited to experiment on SGT-151 (Chemical name 5-pentyl-2-(1-methyl-1-phenyl-ethyl)-2,5-dihydro-pyrido[4,3-b]indol-1-one). Sometimes referred to as Cumyl-PeGlaCone, SGT-151 is a potent research cannabinoid, noted for its similarity to STS-135 – a similar cannabimimetic already trusted by countless researchers. Although only recently being synthesized, it is fast becoming a popular agent, trusted by researchers around the world. SGT-151 is legal across the EU and in Germany (yeehaaa!) where almost all other cannabinoids are illegal. Like other SGT cannabinoids, SGT-151 is a potent agonist, quickly binding with cannabinoid receptors type 1 (CB1 receptors). Unlike THC, SGT-151 is a non-selective ‘full agonist’, meaning it binds to more cannabinoid receptors, therefore it can be inferred that large amounts of dopamine would be released during experiments on live subjects.